Predictive Value of Preoperative Serum AFP, CEA, and CA19-9 Levels in Patients with Single Small Hepatocellular Carcinoma: Retrospective Study
Leijuan Gan,Shaohua Ren,Mengran Lang,Guangtao Li,Feng Fang,Lu Chen,Yayue Liu,Ruyu Han,Kangwei Zhu,Tianqiang Song
DOI: https://doi.org/10.2147/JHC.S376607
2022-08-14
Journal of Hepatocellular Carcinoma
Abstract:Leijuan Gan, &ast Shaohua Ren, &ast Mengran Lang, &ast Guangtao Li, Feng Fang, Lu Chen, Yayue Liu, Ruyu Han, Kangwei Zhu, Tianqiang Song Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China &astThese authors contributed equally to this work Correspondence: Tianqiang Song, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China, Email Purpose: This study aimed to explore the relationship between the tumor marker score (TMS) and the postoperative recurrence of single small hepatocellular carcinoma (HCC). Patients and Methods: A total of 409 patients with one resectable HCC with a diameter of 3 cm or less who visited Tianjin Medical University Cancer Institute & Hospital from January 2010 to December 2014 were included in this study. Their alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) levels were classified into low and high groups using X-tile software. Each patients' TMS was calculated as the sum of each tumor marker (low = 0; high = 1). Results: A total of 142 patients were classified as TMS0, 171 as TMS1, and 96 as TMS2. Kaplan–Meier analysis illustrated that TMS could divide the patients into groups with remarkably different prognoses, and the patients with high TMS had worse recurrence-free survival (RFS) than those with low TMS. Multivariate analysis showed that TMS, age, and HBeAg positive were the independent predictors of RFS rate. Subgroup analysis revealed that high TMS was a stable risk factor relative to TMS0. Receiver operating curves showed that the 1-, 3-, and 5-year area under curve (AUC) values of TMS were 0.698, 0.662, and 0.673, respectively. The AUC of TMS was higher than that of other common prognostic models in time-dependent receiver operating curve. Conclusion: TMS was an independent prognostic factor for the postoperative recurrence of a single small HCC and can provide a well-discriminated risk stratification, thus contributing to prognostic prediction and adjuvant therapeutic development. Keywords: hepatocellular carcinoma, recurrence-free survival, tumor marker score, alpha-fetoprotein, carcinoembryonic antigen, carbohydrate antigen 19-9 Hepatocellular carcinoma (HCC) was the sixth most common cancer and the third leading cause of cancer death worldwide in 2020. 1 Approximately 900,000 new cases of HCC have been reported, and China accounted for more than half of these cases. 2 With the enhanced awareness of patients' physical examination and the improvement of hospitals' diagnosis, the number of patients diagnosed with early HCC is increasing. In the Barcelona Clinic Liver Cancer (BCLC) system, a single HCC less than 2 cm is classified as a very early stage, 3 and a single nodule less than 3 cm is classified as an early stage. 4–6 Although surgical treatments, such as transplantation, surgical resection, and ablation, may be effective for BCLC stage A HCC, the 5-year overall survival rate after developing this cancer is only 50%–70%, 7–9 and the high incidence of postoperative recurrence remains a major issue. 10,11 Thus, biomarkers that can predict postoperative recurrence must be urgently explored. Alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) are well-known tumor markers in the diagnosis and prognosis of hepatobiliary pancreatic malignancies and have been incorporated in various prognostic models. 12–17 As a common practical clinical biomarker, AFP is widely used in HCC, 18 and an increased serum AFP level is usually related to a high risk of HCC development and a poor prognosis. 19 CEA is a relatively non-specific antigen widely used in the clinical diagnosis and treatment monitoring of gastrointestinal cancer. 20 Its high serum level is considered as an independent predictor of recurrence in patients with HCC. 21–23 CA19-9 is mainly used as a sensitive biomarker for pancreatic malignancies, 24 and a high level of it is also associated with poor prognosis in patients with HCC. 25 CA19-9 was found to be related to severe cirrhosis and liver inflammation, 26 leading to a poor prognosis in patients with HCC. Approximately 30% of patients with HCC have an elevated serum level. 25 -Abstract Truncated-
oncology